Comparative Pharmacology
Head-to-head clinical analysis: ATHENTIA NEXT versus YAZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATHENTIA NEXT versus YAZ.
ATHENTIA NEXT vs YAZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levonorgestrel is a progestin that inhibits ovulation and alters cervical mucus, reducing sperm penetration. Ethinyl estradiol suppresses gonadotropin release, preventing follicular development.
Combination of ethinyl estradiol and drospirenone; suppresses gonadotropins (FSH and LH) inhibiting ovulation, and increases cervical mucus viscosity to impede sperm penetration. Drospirenone has antimineralocorticoid and antiandrogenic activity.
Not established. ATHENTIA NEXT is not a recognized pharmaceutical agent. Consult official prescribing information.
One tablet (0.02 mg ethinyl estradiol and 3 mg drospirenone) orally once daily for 24 days, followed by 2 days of placebo.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours in healthy adults; clinically relevant for once-daily dosing.
Terminal elimination half-life of drospirenone is 31.2-32.5 hours; ethinyl estradiol: 13-27 hours. Steady-state achieved after 10 days of daily dosing. Clinically, once-daily dosing maintains stable concentrations.
Renal excretion of unchanged drug: 60-70%; fecal/biliary elimination: 20-30%; hepatic metabolism accounts for <10%.
Approximately 50% of drospirenone is excreted renally (metabolites, with <10% unchanged), and 50% via feces (biliary) after hepatic conjugation. Ethinyl estradiol is primarily excreted renally (60%) and fecally (40%) as glucuronide and sulfate conjugates.
Category C
Category C
Oral Contraceptive
Oral Contraceptive